| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H24N4O4S |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
BX-2819 is an inhibitor of Hsp90 with an IC50 of 41 nM. It inhibits the proliferation of cancer cells and can inhibit the growth of NCI-N87 and HT-29 tumors in nude mice[1]. It has the molecular formula C21H24N4O4S and a molecular weight of 428.50 g/mol.
Physical & Chemical Properties
| CAS Number | 1184181-50-7 |
|---|---|
| Molecular Formula | C21H24N4O4S |
| Molecular Weight | 428.50 g/mol |
| SMILES | CCOC(NCC1=CC=C(C=C1)N2C(NN=C2C3=C(C=C(C(C(C)C)=C3)O)O)=S)=O |
| Target | HSP90, HSP70 |
| Signaling Pathway | Cell Cycle/DNA Damage; Metabolic Enzyme/Protease |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
[1]
|
HSP90 41 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
In HT-29, OVCAR3 and SKBR3, BX-2819 (0.001-10 μM, 16 h) can inhibit ErbB2 protein expression and significantly enhances Hsp70 expression[1]. Proliferation of SKBR3 (IC50=14 nM), SKOV3 (IC50 = 36 nM), 50 MKN45 (IC50=72 nM), and NCI-N87 (IC50= 7 nM) tumor cancer cells can be inhibited by BX-2819 (0.001-10 μM, 72 h)[1]. In HepG2 and RPTEC cells, no significant cytotoxic effects are produced by BX-2819 (100 μM)[1].
Western Blot Analysis[1]
| Cell Line | NCI-N87, MKN-45 |
|---|---|
| Concentration | 0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM |
| Incubation Time | 16 h |
| Result | Significantly inhibited the expression of ErbB2, Raf1 and c-Met proteins. |
In Vivo
In NCI-N87 and SKOV3 tumor mice, ErbB2 protein expression is significantly inhibited by BX-2819 (100 mg/kg, intraperitoneal injection (i.p.), twice a week), and in HT-29 and NCI-N87 tumor mice, tumor growth and final tumor load are significantly reduced[1]. In rats, a single intravenous (i.v.) injection of BX-2819 (2 mg/kg) gives a serum half-life that is relatively short (t1/2=0.8 h), alongside a high clearance rate (CL=159 mL/min/kg) and a large distribution volume (Vss=4.5 L)[1]. BX-2819 pharmacokinetic parameters in rats (n = 4) [1]
| Dose（mg/kg） | Route | T1/2(h) | AUCinf(μg h/mL) | CL (mL/min) | Vss(L/kg) |
| 2 | iv | 0.8 | 0.23 | 159 | 4.5 |
| Animal Model | SKOV3, HT-29 and NCI-N87 xenograft models in nude mice[1] |
|---|---|
| Dosage | 100 mg/kg |
| Administration | Intraperitoneal injection (i.p.), twice a week |
| Result | Significantly inhibited ErbB2 expression, effectively inhibited Hsp90 for a long time, and enhanced Hsp70 expression. Could enter the plasma after intraperitoneal injection. Significantly decreased in tumor growth and final tumor burden. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
